Results 221 to 230 of about 49,785 (245)

Physician estimation of the prevalence and clinical impact of chronic urticaria: results of the global, multicenter UCARE CU-PAPER study. [PDF]

open access: yesFront Allergy
Kern BM   +9 more
europepmc   +1 more source

Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo‐Controlled Study

open access: yesAllergy, Volume 81, Issue 5, Page 1799-1812, May 2026.
Codfish OIT significantly increased desensitization in children with fish allergy (43% vs. 11% placebo, p = 0.003), with 69% achieving 10‐fold threshold increases versus 26% in placebo (p = 0.0003). Sustained unresponsiveness remained limited (23% vs. 9%, p = 0.332). Treatment demonstrated acceptable safety with predominantly mild reactions and reduced
Agnes Sze‐yin Leung   +9 more
wiley   +1 more source

Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms. [PDF]

open access: yesAsia Pac Allergy
Türk M   +13 more
europepmc   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

open access: yesAllergy, Volume 81, Issue 5, Page 1354-1369, May 2026.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang   +37 more
wiley   +1 more source

Systemic mastocytosis: a clinical case report [PDF]

open access: yes, 2003
Aragão, A   +5 more
core  

Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta‐Analysis

open access: yesAllergy, Volume 81, Issue 5, Page 1548-1570, May 2026.
This meta‐analysis included 2292 patients with severe asthma who underwent biologic switching across 23 countries/regions. The most prevalent switching pattern was from mepolizumab to benralizumab, with suboptimal asthma control being the primary reason.
Yang Zheng   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy